Renal Transplant Recipients Often Admitted With Acute MI

Share this content:
Renal Transplant Recipients Often Admitted With Acute MI
Renal Transplant Recipients Often Admitted With Acute MI

THURSDAY, Feb. 9, 2017 (HealthDay News) -- Renal transplant recipients (RTRs) are often admitted with acute myocardial infarction (AMI), according to a study published in the Feb. 15 issue of The American Journal of Cardiology.

Sahil Agrawal, M.D., from St. Luke's University Health Network in Bethlehem, Penn., and colleagues examined recent trends in AMI admissions for 9,243 RTRs with functioning grafts. Data were compared to those of 160,932 patients with end-stage renal disease without transplantation (ESRD-NRT) and 5,640,851 patients without advanced kidney disease (non-ESRD/RT) admitted with AMI.

The researchers found that 0.2 percent of AMI admissions were RTRs, with increasing numbers during the study period (adjusted odds ratio [aOR], 1.04; 95 percent confidence interval [CI], 1.04 to 1.05; Ptrend < 0.001). Acute ST-segment elevation myocardial infarction (STEMI) accounted for 29.3 percent of RTR admissions. History of renal transplantation correlated with decreased likelihood of STEMI at presentation compared with non-ESRD/RT (aOR, 0.73; 95 percent CI, 0.65 to 0.80; P < 0.001). From 2003 to 2011 there was a decrease in in-hospital mortality among RTRs admitted for non-STEMI (3.8 to 2.1 percent; aOR, 0.85; 95 percent CI, 0.78 to 0.93; P < 0.001), while no change was seen for STEMI (7.6 to 9.3 percent; aOR, 0.97; 95 percent CI, 0.90 to 1.03; P = 0.36). Compared with ESRD-NRT, the rates of percutaneous coronary interventions and in-hospital mortality were lower for RTRs (both P < 0.001).

"RTRs were frequently admitted with AMI, particularly NSTEMI," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »